At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LRMR Larimar Therapeutics, Inc.
Trading 12-22 10:06:11 EST
3.87
+0.22
+5.89%
High3.87Low3.60Vol109.54K
Open3.64D1 Closing3.65Amplitude7.26%
Mkt Cap330.81MTradable Cap174.50MTotal Shares85.59M
T/O412.46KT/O Rate0.24%Tradable Shares45.15M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Larimar Therapeutics Swaps Common Shares for Series A Convertible Preferred Stock in Private Placement
Reuters  ·  12-17
Larimar Therapeutics Swaps Common Shares for Series A Convertible Preferred Stock in Private Placement
Larimar Therapeutics Q3 Net Income USD -47.712 Million
Reuters  ·  11-20
Larimar Therapeutics Q3 Net Income USD -47.712 Million
Analysts Offer Insights on Healthcare Companies: Radnet (RDNT), Palvella Therapeutics (PVLA) and Larimar Therapeutics (LRMR)
TIPRANKS  ·  11-06
Analysts Offer Insights on Healthcare Companies: Radnet (RDNT), Palvella Therapeutics (PVLA) and Larimar Therapeutics (LRMR)
Larimar Therapeutics Q3 net loss widens
Reuters  ·  11-05
Larimar Therapeutics Q3 net loss widens
BRIEF-Larimar Therapeutics Q3 Net Income USD -47.712 Million
Reuters  ·  11-05
BRIEF-Larimar Therapeutics Q3 Net Income USD -47.712 Million
Larimar Therapeutics Q3 Basic EPS USD -0.61
THOMSON REUTERS  ·  11-05
Larimar Therapeutics Q3 Basic EPS USD -0.61
Larimar Therapeutics Inc - Targets Bla Submission for Q2 2026
THOMSON REUTERS  ·  11-05
Larimar Therapeutics Inc - Targets Bla Submission for Q2 2026
Larimar Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview
Reuters  ·  10-24
Larimar Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview
Truist Financial Sticks to Its Buy Rating for Larimar Therapeutics (LRMR)
TIPRANKS  ·  10-08
Truist Financial Sticks to Its Buy Rating for Larimar Therapeutics (LRMR)
Do Positive Friedreich's Ataxia Study Results Shift Larimar Therapeutics’ (LRMR) Long-Term Value Proposition?
Simply Wall St.  ·  10-04
Do Positive Friedreich's Ataxia Study Results Shift Larimar Therapeutics’ (LRMR) Long-Term Value Proposition?
Larimar Therapeutics : Oppenheimer Cuts Target Price to $21 From $26
THOMSON REUTERS  ·  10-02
Larimar Therapeutics : Oppenheimer Cuts Target Price to $21 From $26
Analysts Are Bullish on Top Healthcare Stocks: Larimar Therapeutics (LRMR), Inventiva (IVA)
TIPRANKS  ·  09-30
Analysts Are Bullish on Top Healthcare Stocks: Larimar Therapeutics (LRMR), Inventiva (IVA)
U.S. RESEARCH ROUNDUP-Electronic Arts, Kala Bio, Semtech
Reuters  ·  09-30
U.S. RESEARCH ROUNDUP-Electronic Arts, Kala Bio, Semtech
Larimar Therapeutics (LRMR) Gets a Buy from JonesTrading
TIPRANKS  ·  09-30
Larimar Therapeutics (LRMR) Gets a Buy from JonesTrading
Leerink Partners Keeps Their Buy Rating on Larimar Therapeutics (LRMR)
TIPRANKS  ·  09-30
Leerink Partners Keeps Their Buy Rating on Larimar Therapeutics (LRMR)
Larimar Therapeutics Down Nearly 29%, on Pace for Largest Percent Decrease Since May 2023 -- Data Talk
Dow Jones  ·  09-30
Larimar Therapeutics Down Nearly 29%, on Pace for Largest Percent Decrease Since May 2023 -- Data Talk
Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study
Benzinga_recent_news  ·  09-29
Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study
BUZZ-Larimar Therapeutics tumbles on safety concerns over rare genetic disorder drug
Reuters  ·  09-29
BUZZ-Larimar Therapeutics tumbles on safety concerns over rare genetic disorder drug
BRIEF-Larimar Reports Positive Long-Term Data, Updates Nomlabofusp Program for Friedreich’s Ataxia
Reuters  ·  09-29
BRIEF-Larimar Reports Positive Long-Term Data, Updates Nomlabofusp Program for Friedreich’s Ataxia
Larimar Therapeutics Shares Drop 52% Premarket After Co Reports Long-Term Late-Stage Data for Genetic Disorder Drug
THOMSON REUTERS  ·  09-29
Larimar Therapeutics Shares Drop 52% Premarket After Co Reports Long-Term Late-Stage Data for Genetic Disorder Drug

Introduction

Company Name.
Larimar Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
Issue price:
--